Uncategorized
Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first Canadian subject in its Phase 1 / 2 clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction. “We are very pleased to have begun dosing subjects in this trial in Canada,” said Michael Goldstein, MD, MBA,